REG - Arecor Therapeutics - Arecor Appoints Interim Chief Financial Officer

Arecor TherapeuticsAnnouncement

18/11/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241118:nRSR5201Ma&default-theme=true

RNS Number : 5201M  Arecor Therapeutics PLC  18 November 2024

 

Arecor Therapeutics plc

("Arecor" or "the Company")

 

APPOINTMENT OF INTERIM CHIEF FINANCIAL OFFICER

 

Cambridge, UK, 18 November 2024: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces the appointment of David Ellam as Interim Chief Financial
Officer (CFO), effective immediately.

 

David is an experienced finance professional and chartered accountant, with
over two decades of experience in the life sciences industry. He has held CFO
roles at numerous healthcare companies including Juvenescence, a life
sciences company developing therapies to modify ageing and increase healthy
human lifespan, Silence Therapeutics, a biotechnology company harnessing the
body's natural mechanism of RNA interference (RNAi) and, more recently,
Sixfold Bioscience, a company focused on RNA delivery using AI/ML. Early in
his career, he qualified as an accountant at PwC, transitioning to a variety
of financial and internal audit roles at companies including Smith &
Nephew.

 

Sarah Howell, Chief Executive Officer of Arecor, said: "David is a highly
experienced finance executive whose life sciences knowledge and broad
financial expertise will be highly valuable in supporting the business moving
forward including as we continue to execute our strategic initiatives to drive
shareholder value. It is my pleasure to welcome him to the Arecor team."

 

-ENDS-

 

For more information, please contact:

 

 Arecor Therapeutics plc                                      www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer                     Tel: +44 (0) 1223 426060

                                                              Email: info@arecor.com (mailto:info@arecor.com)

 Panmure Liberum Limited (NOMAD and Joint Broker)
 Emma Earl, Freddy Crossley, Mark Rogers (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)
 Nigel Barnes, Satheesh Nadarajah                             Tel: +44 (0)203 705 9321

 David Wilson, Claes Spang

 ICR Healthcare
 Chris Gardner, David Daley, Lindsey Neville                  Tel: +44 (0) 20 3709 5700

                                                              Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical company
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing an internal
portfolio of proprietary products in diabetes and other indications, as well
as working with leading pharmaceutical and biotechnology companies to deliver
therapeutic products. The Arestat™ platform is supported by an extensive
patent portfolio.

 

For further details please see our website, www.arecor.com
(http://www.arecor.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAFZMMMKNVGDZM